Erin: Purdue Pharma's Role in the US Opioid Crisis Study Notes

The opioid crisis began in the 1990s.
Statistics: Over 800,000 overdose deaths attributed to opioids from 1999 to 2023. - In 2020, economic losses due to the opioid crisis were estimated at $1.5 trillion USD. - About 1,000 emergency department visits each day linked to opioid misuse.
The crisis affects not only users but also others, such as unborn children, with neonatal abstinence syndrome incidence increasing fivefold from 2004 to 2014.

Established in 1892 as Purdue Frederick Company, originally selling earwax removers and laxatives.
Acquired by the Sackler family in 1952, shifting focus to pain medication.
Renamed Purdue Pharma LP in 1991.

Opiates: Natural compounds from the opium poppy. - Historical use since 5,000 BC; includes opium, morphine, heroin, and codeine.
Opioids: Synthetic derivatives, such as methadone, oxycodone, and fentanyl.

Opioids bind to receptors in the central nervous system (brain and spinal cord) to: - Reduce pain by inhibiting neuronal activity. - Induce euphoria through dopamine release.
Potential for fatal overdose due to respiratory depression caused by inhibition of neurons that regulate breathing.

An opioid overdose reversal agent that displaces opioids from receptors due to higher affinity.

Previous opioid crises in the 1800s (middle-class white women) and early 1900s (lower-class urban males).
Historical laws restricted access for lower-class individuals, stabilizing death rates until the 1990s.

Introduction: OxyContin launched by Purdue in 1996 to replace MS Contin (morphine). Approved for moderate to severe chronic pain.
Marketing Strategy: Aggressive and misleading, focusing on: - Superiority of Efficacy: Claims of better effectiveness than other pain medications, which was not supported by evidence. - Longer Dosing Schedule: Advertised as a sustainable 12-hour release, despite studies showing inadequate pain control leading to the need for rescue medications. - Low Addiction Risk Claims: Trained sales reps to assert less than 1% addiction risk, whereas actual figures indicated 20-50% misuse among patients.
A massive advertising budget of about $207 million spent on initial marketing and doubled sales force (from 300 to 600).

Revenue Growth: From approximately $48 million in 1996 to over $3 billion by 2010.
Implications: Resulted in widespread prescribing by healthcare providers influenced by misleading claims, resulting in significant abuse and addiction.

Engaged respected physicians as key opinion leaders to promote opioid use.
Paid pharmacy benefit managers to keep prescriptions flowing without limits on quantity or dosage.
Significant political contributions made to influence regulatory stances and investigations.
Examples: - Purdue's $400 million payments to pharmacy benefit managers in 2012. - Contributions exceeding $200,000 to political parties for legislative influence.

Many pain advocacy organizations funded by pharmaceutical companies, including Purdue, which undermined genuine advocacy for pain management.

FDA Involvement: Approved OxyContin with insufficient scrutiny on addiction risk, leading to flawed clinical trial practices. - Lacked adequate staffing, resulting in backlogs and delayed regulatory actions.
The first criminal charges against Purdue executives occurred in 2007, with substantial fines imposed. - Claim of legal accountability led to bankruptcy in 2019 and ongoing legal battles. A proposed $7.4 billion settlement in 2025.

The Sackler family contributed $6.5 billion to the settlement despite their net worth being between $11-13 billion.
Other responsible parties included McKinsey & Company, which settled for over $500 million in 2021.

Proliferation of similar practices by other pharmaceutical companies following Purdue's model.
Continued global issue with the Sackler family allegedly mirroring operations through Mundipharma, resulting in similar aggressive marketing tactics in other countries.

Recent data suggests a decrease in opioid deaths in the US for the first time since the crisis began, but overdose rates remain 10 times higher than in 1999, with an average of 217 daily deaths in 2023.
The crisis has been classified into three waves: - Wave 1: Prescription opioids (OxyContin). - Wave 2: Rise in heroin overdoses. - Wave 3: Increase in synthetic opioids.

Ongoing challenges in regulating opioid prescriptions while ensuring access for patients in genuine need of pain relief.
Importance of reassessing regulatory processes and marketing in the pharmaceutical industry amid rising concerns over addiction and misuse.

The opioid crisis encapsulates a complicated interplay of corporate interests, regulatory failures, and societal impact. Continued vigilance and reform are crucial to prevent further impact on public health.